**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57071

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/** **cyclooxygenase-2 signaling pathway**

Sun MX *et al*. AKBA’s anti-gastric cancer mechanism

Meng-Xue Sun, Xiao-Pu He, Pei-Yun Huang, Qi Qi, Wei-Hao Sun, Gao-Shuang Liu, Jie Hua

**Meng-Xue Sun, Xiao-Pu He, Pei-Yun Huang, Wei-Hao Sun, Gao-Shuang Liu,** Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu Province, China

**Qi Qi,** Nanjing Medical University, Nanjing 210000, Jiangsu Province, China

**Jie Hua,** Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu Province, China

**Author contributions:** Sun MX and He XP contributed equally to this work; Sun MX, He XP, Huang PY, Sun WH, and Hua J designed the research study; Sun MX, He XP, Huang PY, and Qi Q completed *in vivo* and *in vitro* experiments for this study; Sun WH, Hua J, and Liu GS contributed new reagents and analytic tools; Sun MX, He XP, and Hua J analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.

**Supported by** the Natural Science Foundation of Jiangsu, No. BK20171508

**Corresponding author: Jie Hua, Assistant Statistician, Doctor,** Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing 210000, Jiangsu Province, China. [huajie@njmu.edu.cn](mailto:huajie@njmu.edu.cn)

**Received:** May 26, 2020

**Revised:** August 8, 2020

**Accepted:** August 26, 2020

**Published online:**

**Abstract**

BACKGROUND

Gastric cancer is one of the most common malignant tumors of the digestive system worldwide, posing a serious danger to human health. Cyclooxygenase (COX)-2 plays an important role in the carcinogenesis and progression of gastric cancer. Acetyl-11-keto-β-boswellic acid (AKBA) is a promising drug for cancer therapy, but its effects and mechanism of action on human gastric cancer remain unclear.

AIM

To evaluate whether the phosphatase and tensin homolog (PTEN)/Akt/COX-2 signaling pathway is involved in the anti-tumor effect of AKBA in gastric cancer.

METHODS

Human poorly differentiated BGC823 and moderately differentiated SGC7901 gastric cancer cells were routinely cultured in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.Gastric cancer cell proliferation was determined by methyl thiazolyl tetrazolium colorimetric assay. Apoptosis was measured by flow cytometry. Cell migration was assessed using the wound-healing assay. Expression of Bcl-2, Bax, proliferating cell nuclear antigen, PTEN, p-Akt, and COX-2 were detected by Western blot analysis. A xenograft nude mouse model of human gastric cancer was established to evaluate the anti-cancer effect of AKBA *in vivo*.

RESULTS

AKBA significantly inhibited the proliferation of gastric cancer cells in a dose- and time-dependent manner, inhibited migration in a time-dependent manner, and induced apoptosis in a dose-dependent manner *in vitro*; it also inhibited tumor growth *in vivo*. AKBA up-regulated the expression of PTEN and Bax, and down-regulated the expression of proliferating cell nuclear antigen, Bcl-2, p-Akt, and COX-2 in a dose-dependent manner. The PTEN inhibitor bpv (Hopic) reversed the high expression of PTEN and low expression of p-Akt and COX-2 that were induced by AKBA. The Akt inhibitor MK2206 combined with AKBA down- regulated the expression of p-Akt and COX-2, and the combined effect was better than that of AKBA alone.

CONCLUSION

AKBA inhibits the proliferation and migration and promotes the apoptosis of gastric cancer cells through the PTEN/Akt/COX-2 signaling pathway.

**Key words:** Acetyl-11-keto-β-boswellic acid; Gastric cancer; Cell proliferation; Apoptosis; Cyclooxygenase-2; Tumor xenograft

Sun MX, He XP, Huang PY, Qi Q, Sun WH, Liu GS, Hua J. Acetyl-11-keto-β-boswellic acid inhibits proliferation and induces apoptosis of gastric cancer cells through the phosphatase and tensin homolog /Akt/ cyclooxygenase-2 signaling pathway. *World J Gastroenterol* 2020; In press

**Core tip:**Cyclooxygenase-2 is involved in the carcinogenesis and development of gastric cancer, and is closely related to its prognosis. Acetyl-11-keto-β-boswellic acid is a promising drug for gastric cancer therapy. It inhibits the proliferation and induces the apoptosis of gastric cancer cells, possibly *via* mechanisms associated with down-regulation of cyclooxygenase-2 expression through the phosphatase and tensin homolog/Akt signaling pathway.

**INTRODUCTION**

Gastric cancer is the fourth most common cancer and second leading cause of cancer-related mortality in the world[1]. It is a multifactorial disease characterized by being highly drug resistant, and apoptotic deficiency could be the obstacle that hampers the efficacy of most anti-cancer agents. Currently, the main treatments include surgery, radiotherapy, and chemotherapy. However, the prognosis of gastric cancer is still poor; thus, it is necessary to find new drugs to treat gastric cancer.

Acetyl-11-keto-β-boswellic acid (AKBA) is a pentacyclic terpenoid extracted from the gum ayurvedic therapeutic plant *Boswellia serrata*. The molecular structure of AKBA is shown in Figure 1. AKBA is anti-inflammatory agent that exhibits potent cytotoxic activities against various types of tumors, such as hepatocellular carcinoma[2], glioblastoma[3], prostate cancer[4], lung carcinogenesis[5], colon cancer[6,7], and leukemia[8,9]. However, the efficacy and mechanism of action of AKBA in treating gastric cancer have not been studied. This study is the first attempt to explore the efficacy and mechanism of action of AKBA in gastric cancer.

Cyclooxygenase (COX) catalyzes the formation of prostaglandin and other eicosanoids from arachidonic acid, which has been considered as a potential target for the prevention and treatment of cancer. It tends to be highly expressed in inflammation and tumor tissues but is undetectable in the majority of normal tissues[10-12]. COX-2, the mitogen-inducible isoform, is constitutively expressed in gastric cancer. It has been shown that overexpression of COX-2 is directly or indirectly involved in the carcinogenesis and development of gastric cancer, and is closely related to its prognosis[13]. However, the molecular mechanisms underlying the aberrant expression of COX-2 in gastric cancer remain unclear. Regulation of COX-2 expression depends on different cellular pathways, involving both transcriptional and post-transcriptional mechanisms[14]. Among all upstream regulatory factors, activation of the PI3K/Akt pathway is important for COX-2 up-regulation[15-18]. PTEN (phosphate and tension homology deleted on chromosome ten) is a tumor suppressor with phosphatase activity that can regulate cell survival, proliferation, and energy metabolism[19,20]. Many tumor tissues present with deficiency of PTEN[21]. PTEN acts as a lipid phosphatase to dephosphorylate phosphatidylinositol (3-5)-trisphosphate, antagonizing the PI3K/Akt pathway[22]. Recent studies have demonstrated that the PTEN/Akt pathway can regulate COX-2 expression in human cervical cancer, gallbladder cancer, and colorectal cancer[23-25].

In this study, human gastric cancer cell lines BGC823 and SGC7901, in which COX-2 was found to be overexpressed[10,13,26,27], were used to investigate the anti-tumor effects of AKBA on human gastric cancer *in vitro* and *in vivo*. Additionally, the expression of proliferating cell nuclear antigen (PCNA), Bcl-2, Bax, COX-2, PTEN, and p-Akt was detected to elucidate the possible mechanism underlying the anti-tumor effects of AKBA against gastric cancer.

**MATERIALS AND METHODS**

***Reagents***

AKBA (C32H48O5, CAS: 67416-61-9, purity: > 98%), dimethylsulfoxide (DMSO), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, United States). Roswell Park Memorial Institute (RPMI)-1640 medium, fetal bovine serum, and penicillin/streptomycin were purchased from Gibco BRL (Grand Island, NY, United States). Hoechst 33342 and apoptosis detection kit were purchased from Beyotime Institute of Biotechnology (Nantong, China). PTEN inhibitor bpv (HOpic) and Akt inhibitor MK2206 were purchased from Selleck Chemicals (Houston, TX, United States). Other reagents were of analytic grade and obtained from Nanjing Chemical Reagent Co. (Nanjing, China), unless otherwise described. AKBA was dissolved in DMSO as a 2 mmol/L stock solution and stored at -20 °C.

***Cell culture and treatments***

Human poorly differentiated BGC823 and moderately differentiated SGC7901 gastric cancer cell lines were obtained from Shanghai Institute of Cell Biology (Shanghai, China). All cells were routinely cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All the cells were kept at 37 °C in a humidified atmosphere of 5% CO2.

***Methyl thiazolyl tetrazolium (MTT) assay***

BGC823 and SGC7901 cells (4000-5000/well) were seeded into 96-well plates and incubated overnight in a 5% CO2 atmosphere at 37 °C. The following day, the gastric cancer cells were treated with different concentrations of AKBA (0, 10, 20, 30, 40, and 50 µM) in serum-free conditions for 24, 48, or 72 h at 37 °C. Subsequently, 200 µL of MTT solution (0.5 mg/ML) was added to each well and incubated for 4 h at 37 °C. DMSO (200 µL) was then added to each well. The proliferation-inhibitory effects of each combination were assessed using a microplate reader (MJ Research Inc.) at 570 nm.

***Flow cytometry***

To detect the apoptosis rate of gastric cancer cells, we used the Annexin V fluorescein isothiocyanate (FITC) Apoptosis Detection Kit to measure apoptosis *via* flow cytometry. BGC823 and SGC7901 cells were plated in six-well plates at 2 × 105 cells per well. All the cells were treated with different concentrations of AKBA (0, 20, 30, or 40 µM) for 48 h. Detached cells were collected, combined with the trypsinized attached cells, and centrifuged at 1400 r/min, 4 °C, for 10 min. Cells were re-suspended in 1 mL of binding buffer and allowed to react with 10 µL of FITC-labeled Annexin V and 10 µL of PI for 15 min at room temperature in the dark. Afterward, the cells were analyzed on a flow cytometer (Becton Dickinson, San Jose, CA, United States). Apoptosis was assessed by Annexin V-FITC and PI staining.

***Western blot analysis***

BGC823 and SGC7901 cells were grown to sub-confluence in 100-mm dishes and cultured in serum-free medium for 24 h. The cells were treated with different concentrations of AKBA (0, 20, 30, or 40 µM) in serum-free conditions for 48 h. In another experiment, the cells were pre-treated with the PTEN inhibitor bpv (HOpic, 17.4 ng/ML) or Akt inhibitor MK2206 (38.4 ng/ML) for 30 min and then with AKBA (40 µM) for 48 h. The extraction of proteins from cells and Western blotting were performed as described previously[28,29]. Antibodies used include rabbit anti-PCNA, anti-Bcl-2, anti-Bax, anti-PTEN, anti-COX-2, and anti-reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) (Abcam Inc., Cambridge, MA, United States), as well as anti-phospho (p)-Akt and anti-Akt (Sigma–Aldrich). Horseradish peroxidase-conjugated goat anti-rabbit IgG purchased from Abcam was used as secondary antibody. The relative expression of PCNA, Bcl-2, Bax, PTEN, and COX-2 was normalized to that of GAPDH. P-Akt was normalized to the total Akt level.

***Wound healing assay***

A wound healing assay was performed as described previously[30]. BGC823 and SGC7901 cells were seeded in six-well plates (7 × 105–8 × 105 cells/well) to produce a conﬂuent monolayer. The cell monolayer was scratched with a pipette tip and washed with phosphate-buffered saline. Cells were then incubated with different concentrations (20 µM) of AKBA. Scratch wounds were photographed under a phase contrast microscope (Leica, Nussloch, Germany) at 0, 48, and 72 h post treatment, respectively.

***Anti-cancer activity in mice***

The effect of AKBA was further evaluated in nude mice bearing xenografts of BGC823 and SGC-7901 cells. The use of all experimental animals was in compliance with the protocols set by Nanjing Medical University Institutional Animal Care and Use Committee. Female athymic BALB/c (nu+/nu+) mice (*n* = 20), aged 5 wk, were purchased from the Department of Laboratory Animal Center of Nanjing Medical University (Nanjing, China). The mice were kept in a specific pathogen-free conditional microenvironment (temperature 24 °C, humidity 60 ± 10%, and 12 h/12 h light/dark cycle). Then, 0.1 mL of cell suspension containing 5 × 106 – 6 × 106 BGC823 or SGC7901 cells was subcutaneously injected into the axillary space of the mice. When tumor volume reached approximately 100 mm3, mice were randomly divided into different groups (*n* = 5): AKBA (100 mg/kg) or control (equal volume of normal saline). Mice were observed daily for clinical symptoms. Tumor volume and body weight were measured every 2 d. The tumor volume was calculated as (shortest diameter)2 × (longest diameter) × 0.5. At the end of treatment, nude mice were intraperitoneally injected with 3% pentobarbital sodium and were euthanized by excessive anesthesia at a dose of 90 mL/kg. The tumor tissue was weighed and excised for Western blot analysis.

***Statistical analysis***

All data from at least three independent experiments are represented as the mean ± SD and statistically analyzed by two-tailed Student’s *t*-test or one-way analysis of variance with Dunnett’s multiple comparison tests. Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, United States). *P* < 0.05 was considered statistically significant.

**RESULTS**

***AKBA inhibits proliferation and induces apoptosis of gastric cancer cells***

MTT assay was performed to evaluate the survival of gastric cancer cells exposed to different therapeutics (0–50 µM for 24, 48, and 72 h). AKBA significantly inhibited the proliferation of BGC823 and SGC7901 cells in a dose- and time-dependent manner (Figure 2A and B). After 72 h of treatment with 50 µM AKBA, the proliferation of BGC823 and SGC7901 cells was almost completely blocked.

Annexin V-FITC/PI assay was also conducted to investigate the apoptosis induced by AKBA on the basis of flow cytometry. In the dual-parameter fluorescent dot plots, early apoptotic cells stained with Annexin V (Annexin V+/PI−, Q3), and late apoptotic cells stained with Annexin V and PI (Annexin V+/PI+, Q2) were counted (Figure 2C). AKBA induced the apoptosis of gastric cancer cells in a dose-dependent manner (Figure 2D).

To study the effect of AKBA on cell proliferation and apoptosis, the expression of PCNA (involved in proliferation), Bcl-2, and Bax (involved in apoptosis) in BGC-823 and SGC-7901 cells was evaluated by Western blot analysis. After 48 h of AKBA treatment, the expression of Bax was up-regulated and that of Bcl-2 and PCNA was downregulated in a dose-dependent manner in BGC-823 and SGC-7901 cells (Figure 2E-G). All of these data indicated that AKBA inhibits the proliferation and induces the apoptosis of gastric cancer cells.

***Effects of AKBA on expression of PTEN, COX-2, and p-AKT in BGC-823 and SGC-7901 cells***

PTEN, COX-2, and p-Akt expression in gastric cancer cells was detected by Western blot analysis. AKBA dose-dependently inhibited COX-2 expression and p-Akt expression, and increased PTEN expression in BGC-823 and SGC-7901 cells (Figure 3).

***Effects of PTEN/Akt inhibitor on AKBA-induced downregulation of COX-2 expression in gastric cancer cells***

To elucidate the signaling pathway involved in the down-regulation of COX-2 expression induced by AKBA, further studies were designed to determine the effect of PTEN and Akt inhibitors on COX-2 expression in gastric cancer cells. The PTEN inhibitor bpV (HOpic) blocked the high expression of PTEN induced by AKBA and reversed the low expression of p-Akt and COX-2 inhibited by AKBA (Figure 4). The Akt inhibitor MK2206 combined with AKBA downregulated the expression of p-Akt and COX-2, and the combined effect was better than that of AKBA alone. These results collectively indicated that AKBA elicited inhibition of proliferation and induction of apoptosis of gastric cancer cellsmay be mediated by down-regulation of COX-2 expression through the PTEN/Akt signaling pathway.

***AKBA inhibits cell migration and wound closure of gastric cancer cells***

We further examined the effect of AKBA on cell migration after monolayer wounding. When BGC823 and SGC7901 cell monolayers were wounded and treated with AKBA (20 µM) for 48 or 72 h, the AKBA-treated groups closed the gaps at a slower pace at 48 and 72 h , compared with the control group (Figure 5).

***AKBA inhibits gastric xenograft tumor growth in vivo***

The effect of AKBA on BGC823 and SGC7901 cell xenografts was examined (Figure 6). Twenty nude mice implanted with BGC823 or SGC7901 cells were treated daily with AKBA for 2 wk. No deaths occurred within that period. The average tumor volume of nude mice treated with AKBA was markedly lower than that in the control nude mice (Figure 6A and B). There was no significant difference in body weight between the control and AKBA-treated nude mice (Figure 6C). COX-2 protein was overexpressed in gastric cancer tissues of control nude mice (Figure 6D and E). The results indicated that AKBA reduced the expression of COX-2 in the tumor tissues of nude mice, suggesting that AKBA inhibits tumor growth in nude mice by down-regulating the expression of COX-2.

**DISCUSSION**

Gastric cancer is one of the most common malignancies with a high mortality rate. COX-2 is expressed in gastric cancer and is a factor involved in cancer cell proliferation and apoptosis, cancer invasiveness, and metastasis[31]. Studies have shown that COX-2 inhibition by selective COX-2 inhibitors or siRNA suppresses cell growth and leads to apoptosis in human gastric adenocarcinoma cells[29,32]. In this study, we demonstrated for the first time that AKBA can downregulate the expression of COX-2 *via* the PTEN/Akt signaling pathway in gastric cancer cells, and consequently induces the apoptosis and inhibits the proliferation of gastric cancer cells.

Previous studies have confirmed that AKBA can inhibit the proliferation and enhance the apoptosis of pancreatic cancer cells *in vitro* by reducing COX-2 expression level[33]. The results of those studies are consistent with our finding that AKBA can significantly inhibit COX-2 expression in gastric cancer cells. However, the molecular mechanism by which AKBA down-regulates the expression of COX-2 in gastric cancer cells remains unknown.

Numerous studies have confirmed that the PI3K/Akt signaling pathway can induce apoptosis in a variety of cancer cells[34-37]. COX-2 expression can be induced by activating the PI3K/Akt signaling pathway in gastric cancer cells, thereby regulating the proliferation of gastric cancer cells[28]. PTENdeletion increases the activation of the PI3K/Akt pathway[22,38]. When the PTEN gene is mutated or lost, the Akt signaling pathway is activated, resulting in the proliferation of cells to form tumors[39]. miR-21 promotes cell proliferation by activating PTEN/Akt signaling in cancer cells[40]. CD2 selectively induces the expression of COX-2 through PTEN-mediated PI3K/Akt activation[41]. The selective COX-2 inhibitor celecoxib inhibits tumor growth *via* the PTEN/PI3K/Akt pathway in an H22 murine hepatocarcinoma model[17]. Our results are consistent with those previous findings. Our results showed that AKBA can effectively inhibit the proliferation and migration of gastric cancer cells and induce their apoptosis. Additionally, AKBA significantly inhibited the expression of PCNA, Bcl-2, and p-Akt, and increased Bax and PTEN expression in gastric cancer cells. To clarify the molecular mechanisms of the anti-cancer effect of AKBA on gastric cancer, we examined ethe xpression of proteins related to the PTEN/Akt/COX-2 pathway *in vitro* (Figure 7). The PTEN inhibitor bpv (Hopic) blocked AKBA-induced PTEN expression, and reversed AKBA-induced downregulation of p-Akt and COX-2 expression. The Akt inhibitor MK2206 combined with AKBA downregulated the expression of p-Akt and COX-2, and the combined effect was better than that of AKBA alone.

*In vitro* data show that AKBA inhibits the occurrence and development of gastric cancer by inducing apoptosis of gastric cancer cells. Our animal experiments verified the findings of *in vitro* experiments. Previous research confirmed that AKBA has an anti-tumor effect in nude mice[2-4,33,42,43]. Our results indicate that the tumor size of AKBA-treated nude mice is significantly smaller compared to the control group. AKBA significantly inhibits tumor growth in xenograft nude mice without causing significant weight loss, mortality, or other adverse effects.

**CONCLUSION**

In summary, these results suggest that AKBA inhibition of proliferation and induction of apoptosis of gastric cancer cellsmay be mediated by down-regulation of COX-2 expression through the PTEN/Akt signaling pathway.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer is a digestive malignancy with high incidence and mortality globally. Despite therapeutic improvement, it remains a leading cause of cancer-associated deaths. Gastric cancer can be diagnosed early by endoscopy and treated by timely surgical excision, but the patient’s long-term survival is still threatened by high metastasis, recurrence, and drug resistance. Active medicinal compounds from natural sources have provided alternative treatment options.

***Research motivation***

Gastric cancer is a global health threat. Cyclooxygenase (COX)-2 plays an important role in the carcinogenesis and progression of gastric cancer. The effects of acetyl-11-keto-β-boswellic acid (AKBA) on human gastric cancer remain unclear.

***Research objectives***

The objective of this study was to evaluate the anti-tumor effects and mechanisms of AKBA in human gastric cancer both *in vitro* and *in vivo*.

***Research methods***

Human gastric cancer cell lines BGC823 and SGC7901 were routinely cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum. Sub-confluent cell cultures were treated with AKBA at a final concentration of 10-50 μM for 24, 48, and 72 h, and the cell proliferation was determined usingmethyl thiazolyl tetrazolium colorimetric assay. Apoptosis was assessed *via* flow cytometry analysis. The wound healing assay was performed to evaluate the effects of AKBA on the migration of gastric cancer cells. The expression of proliferating cell nuclear antigen (PCNA), COX-2, Bcl**-**2, Bax, phosphatase and tensin homolog (PTEN), Akt, and phosphorylated Akt was detected by Western blot analysis. A xenograft nude mouse model of human gastric cancer was established to evaluate the anti-cancer effect of AKBA *in vivo*.

***Research results***

AKBA significantly inhibited cellular proliferation and migration and induced apoptosis *in vitro*, as well as inhibited tumor growth *in vivo*. Additionally, AKBA significantly inhibited the expression of PCNA, COX-2, Bcl-2, and phosphorylated Akt as well as increased PTEN and Bax expression in gastric cancer cells.

***Research conclusions***

AKBA could prevent the development of gastric cancer through the PTEN/Akt/COX-2 signaling pathway.

***Research perspectives***

COX-2 is involved in the carcinogenesis and development of gastric cancer. AKBA is a promising drug for gastric cancer therapy.

**REFERENCES**

1 **Wee J**, Nei WL, Yeoh KW, Yeo RM, Loong SL, Qian CN. Why are East Asians more susceptible to several infection-associated cancers (carcinomas of the nasopharynx, stomach, liver, adenocarcinoma of the lung, nasal NK/T-cell lymphomas)? *Med Hypotheses* 2012; **79**: 833-842 [PMID: 23079399 DOI: 10.1016/j.mehy.2012.09.003]

2 **Wang S**, Wang H, Sun B, Li D, Wu J, Li J, Tian X, Qin C, Chang H, Liu Y. Acetyl-11-keto-β-boswellic acid triggers premature senescence via induction of DNA damage accompanied by impairment of DNA repair genes in hepatocellular carcinoma cells in vitro and in vivo. *Fundam Clin Pharmacol* 2020; **34**: 65-76 [PMID: 31141202 DOI: 10.1111/fcp.12488]

3 **Li W**, Liu J, Fu W, Zheng X, Ren L, Liu S, Wang J, Ji T, Du G. 3-O-acetyl-11-keto-β-boswellic acid exerts anti-tumor effects in glioblastoma by arresting cell cycle at G2/M phase. *J Exp Clin Cancer Res* 2018; **37**: 132 [PMID: 29970196 DOI: 10.1186/s13046-018-0805-4]

4 **Liu YQ**, Wang SK, Xu QQ, Yuan HQ, Guo YX, Wang Q, Kong F, Lin ZM, Sun DQ, Wang RM, Lou HX. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties. *Acta Pharmacol Sin* 2019; **40**: 689-698 [PMID: 30171201 DOI: 10.1038/s41401-018-0157-9]

5 **Bhardwaj P**, Kumar M, Dhatwalia SK, Garg ML, Dhawan DK. Acetyl-11-keto-β-boswellic acid modulates membrane dynamics in benzo(a)pyrene-induced lung carcinogenesis. *Mol Cell Biochem* 2019; **460**: 17-27 [PMID: 31165316 DOI: 10.1007/s11010-019-03566-z]

6 **Liu JJ**, Nilsson A, Oredsson S, Badmaev V, Duan RD. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. *Int J Mol Med* 2002; **10**: 501-505 [PMID: 12239601]

7 **Liu JJ**, Huang B, Hooi SC. Acetyl-keto-beta-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells. *Br J Pharmacol* 2006; **148**: 1099-1107 [PMID: 16783403 DOI: 10.1038/sj.bjp.0706817]

8 **Bhushan S**, Kumar A, Malik F, Andotra SS, Sethi VK, Kaur IP, Taneja SC, Qazi GN, Singh J. A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. *Apoptosis* 2007; **12**: 1911-1926 [PMID: 17636381 DOI: 10.1007/s10495-007-0105-5]

9 **Xia L**, Chen D, Han R, Fang Q, Waxman S, Jing Y. Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. *Mol Cancer Ther* 2005; **4**: 381-388 [PMID: 15767547 DOI: 10.1158/1535-7163]

10 **Ye Y**, Liu M, Yuan H, Ning S, Wang Y, Chen Z, Ji R, Guo Q, Li Q, Zhou Y. COX-2 regulates Snail expression in gastric cancer via the Notch1 signaling pathway. *Int J Mol Med* 2017; **40**: 512-522 [PMID: 28586004 DOI: 10.3892/ijmm.2017.3011]

11 **Zha S**, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. *Cancer Lett* 2004; **215**: 1-20 [PMID: 15374627 DOI: 10.1016/j.canlet.2004.06.014]

12 **Smith WL**, Langenbach R. Why there are two cyclooxygenase isozymes. *J Clin Invest* 2001; **107**: 1491-1495 [PMID: 11413152 DOI: 10.1172/JCI13271]

13 **van Rees BP**, Saukkonen K, Ristimäki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. *J Pathol* 2002; **196**: 171-179 [PMID: 11793368 DOI: 10.1002/path.1033]

14 **Joo YE**, Oh WT, Rew JS, Park CS, Choi SK, Kim SJ. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. *Digestion* 2002; **66**: 222-229 [PMID: 12592098 DOI: 10.1159/000068366]

15 **Wang YX**, Li YZ, Zhang ZY, Wang JQ, Cui J, Qian XL. HPV16 E6 Promotes Breast Cancer Proliferation via Upregulation of COX-2 Expression. *Biomed Res Int* 2017; **2017**: 2948467 [PMID: 29250535 DOI: 10.1155/2017/2948467]

16 **Jia H**, Wang H, Yao Y, Wang C, Li P. miR-136 Inhibits Malignant Progression of Hepatocellular Carcinoma Cells by Targeting Cyclooxygenase 2. *Oncol Res* 2018; **26**: 967-976 [PMID: 29295728 DOI: 10.3727/096504018X15148192843443]

17 **Sui W**, Zhang Y, Wang Z, Wang Z, Jia Q, Wu L, Zhang W. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model. *Oncol Rep* 2014; **31**: 2252-2260 [PMID: 24647425 DOI: 10.3892/or.2014.3093]

18 **Kuang W**, Deng Q, Deng C, Li W, Shu S, Zhou M. Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2. *Am J Transl Res* 2017; **9**: 3816-3826 [PMID: 28861172]

19 **Song MS**, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. *Nat Rev Mol Cell Biol* 2012; **13**: 283-296 [PMID: 22473468 DOI: 10.1038/nrm3330]

20 **Salmena L**, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. *Cell* 2008; **133**: 403-414 [PMID: 18455982 DOI: 10.1016/j.cell.2008.04.013]

21 **Hollander MC**, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. *Nat Rev Cancer* 2011; **11**: 289-301 [PMID: 21430697 DOI: 10.1038/nrc3037]

22 **Amerio P**, Scalzerle V. [Anxiety and neurosis in the climacteric age (preliminary data)]. *Minerva Ginecol* 1975; **27**: 64-66 [PMID: 1187053 DOI: 10.1038/sj.bjc.6600126]

23 **Xia S**, Zhao Y, Yu S, Zhang M. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. *Cancer Biother Radiopharm* 2010; **25**: 317-323 [PMID: 20578837 DOI: 10.1089/cbr.2009.0707]

24 **de Araujo WM**, Robbs BK, Bastos LG, de Souza WF, Vidal FC, Viola JP, Morgado-Diaz JA. PTEN Overexpression Cooperates With Lithium to Reduce the Malignancy and to Increase Cell Death by Apoptosis via PI3K/Akt Suppression in Colorectal Cancer Cells. *J Cell Biochem* 2016; **117**: 458-469 [PMID: 26224641 DOI: 10.1002/jcb.25294]

25 **Ali A**, Mishra PK, Sharma S, Arora A, Saluja SS. Effects of PTEN gene alteration in patients with gallbladder cancer. *Cancer Genet* 2015; **208**: 587-594 [PMID: 26586294 DOI: 10.1016/j.cancergen.2015.09.007]

26 **Zhang H**, Li X, Ding J, Xu H, Dai X, Hou Z, Zhang K, Sun K, Sun W. Delivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2). *Int J Pharm* 2013; **441**: 261-268 [PMID: 23194884 DOI: 10.1016/j.ijpharm.2012.11.034]

27 **Xu X**, Zhu GQ, Zhang K, Zhou YC, Li XL, Xu W, Zhang H, Shao Y, Zhang ZY, Sun WH. Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma. *Oncotarget* 2017; **8**: 92770-92777 [PMID: 29190954 DOI: 10.18632/oncotarget.21576]

28 **Xu W**, Chen GS, Shao Y, Li XL, Xu HC, Zhang H, Zhu GQ, Zhou YC, He XP, Sun WH. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells. *Cancer Lett* 2013; **332**: 11-18 [PMID: 23376640 DOI: 10.1016/j.canlet.2012.12.030]

29 **Sun WH**, Zhu F, Chen GS, Su H, Luo C, Zhao QS, Zhang Y, Shao Y, Sun J, Zhou SM, Ding GX, Cheng YL. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. *Cancer Lett* 2008; **263**: 302-311 [PMID: 18258354 DOI: 10.1016/j.canlet.2008.01.012]

30 **Jiang B**, Chen J, Yuan W, Ji J, Liu Z, Wu L, Tang Q, Shu X. Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9. *Oncol Lett* 2018; **15**: 1573-1579 [PMID: 29434852 DOI: 10.3892/ol.2017.7510]

31 **Sun WH**, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, Ding GX, Cheng YL. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis. *Jpn J Clin Oncol* 2005; **35**: 707-713 [PMID: 16314343 DOI: 10.1093/jjco/hyi196]

32 **Chan MW**, Wong CY, Cheng AS, Chan VY, Chan KK, To KF, Chan FK, Sung JJ, Leung WK. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. *Oncol Rep* 2007; **18**: 1557-1562 [PMID: 17982644 DOI: 10.3892/or.18.6.1557]

33 **Park B**, Prasad S, Yadav V, Sung B, Aggarwal BB. Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. *PLoS One* 2011; **6**: e26943 [PMID: 22066019 DOI: 10.1371/journal.pone.0026943]

34 **Kuo HP**, Chuang TC, Tsai SC, Tseng HH, Hsu SC, Chen YC, Kuo CL, Kuo YH, Liu JY, Kao MC. Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. *J Agric Food Chem* 2012; **60**: 9649-9658 [PMID: 22950834 DOI: 10.1021/jf302832n]

35 **Dung TD**, Day CH, Binh TV, Lin CH, Hsu HH, Su CC, Lin YM, Tsai FJ, Kuo WW, Chen LM, Huang CY. PP2A mediates diosmin p53 activation to block HA22T cell proliferation and tumor growth in xenografted nude mice through PI3K-Akt-MDM2 signaling suppression. *Food Chem Toxicol* 2012; **50**: 1802-1810 [PMID: 22289577 DOI: 10.1016/j.fct.2012.01.021]

36 **Liu H**, Han D, Liu Y, Hou X, Wu J, Li H, Yang J, Shen C, Yang G, Fu C, Li X, Che H, Ai J, Zhao S. Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma. *J Neurooncol* 2013; **112**: 39-48 [PMID: 23392846 DOI: 10.1007/s11060-012-1034-x]

37 **Lazrek Y**, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, Vié N, Robert B, Monnet C, Bouayadi K, Kharrat H, Mondon P, Pèlegrin A, Chardès T. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. *Neoplasia* 2013; **15**: 335-347 [PMID: 23479511 DOI: 10.1593/neo.121960]

38 **Korkaya H**, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. *PLoS Biol* 2009; **7**: e1000121 [PMID: 19492080 DOI: 10.1371/journal.pbio.1000121]

39 **Kim HJ**, Lee SY, Oh SC. The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. *Front Physiol* 2016; **7**: 168 [PMID: 27242542 DOI: 10.3389/fphys.2016.00168]

40 **Liu H**, Huang X, Liu X, Xiao S, Zhang Y, Xiang T, Shen X, Wang G, Sheng B. miR-21 promotes human nucleus pulposus cell proliferation through PTEN/AKT signaling. *Int J Mol Sci* 2014; **15**: 4007-4018 [PMID: 24603539 DOI: 10.3390/ijms15034007]

41 **Huang YY**, Xia MZ, Wang H, Liu XJ, Hu YF, Chen YH, Zhang C, Xu DX. Cadmium selectively induces MIP-2 and COX-2 through PTEN-mediated Akt activation in RAW264.7 cells. *Toxicol Sci* 2014; **138**: 310-321 [PMID: 24449419 DOI: 10.1093/toxsci/kfu013]

42 **Schmiech M**, Lang SJ, Ulrich J, Werner K, Rashan LJ, Syrovets T, Simmet T. Comparative Investigation of Frankincense Nutraceuticals: Correlation of Boswellic and Lupeolic Acid Contents with Cytokine Release Inhibition and Toxicity against Triple-Negative Breast Cancer Cells. *Nutrients* 2019; **11**: [PMID: 31581678 DOI: 10.3390/nu11102341]

43 **Conti S**, Vexler A, Edry-Botzer L, Kalich-Philosoph L, Corn BW, Shtraus N, Meir Y, Hagoel L, Shtabsky A, Marmor S, Earon G, Lev-Ari S. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells. *PLoS One* 2018; **13**: e0198627 [PMID: 29969452 DOI: 10.1371/journal.pone.0198627]

**Footnotes**

**Institutional animal care and use committee statement:** The study was reviewed and approved by the Animal Ethical and Welfare Committee of Nanjing Medical University.

**Conflict-of-interest statement:** The authors have no conflict to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at huajie@njmu.edu.cn. Participants gave informed consent for data sharing.

**ARRIVE guidelines statement:** The manuscript has been revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 26, 2020

**First decision:** July 29, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0


**P-Reviewer:** Srinivasamurthy B, Tanabe S **S-Editor:** Zhang H **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**




**Figure 1 Molecular structure of acetyl-11-keto-β-boswellic acid.**




****


**Figure 2 Acetyl-11-keto-β-boswellic acid inhibits the proliferation and induces the apoptosis of gastric cancer cells.** A and B:Dose- and time-dependent effects of acetyl-11-keto-β-boswellic acid (AKBA) on BGC823 and SGC7901 cell proliferation; C: Flow cytometry-based annexin V-FITC/PI labeling of apoptotic cells; D: Histogram showing apoptosis rates; E: Expression levels of proliferating cell nuclear antigen (PCNA), Bcl-2, and Bax in BGC823 and SGC7901 cells measured *via* Western blot analysis after AKBA treatment; F and G: Histograms showing the relative expression levels of PCNA, Bcl-2, and Bax compared with GAPDH in BGC823 and SGC7901 cells. Each data point represents the mean ± SD from three independent experiments.*aP* < 0.05, *bP* < 0.01 *vs* control (0 µM). *cP* < 0.05, *dP* < 0.01 *vs* control (24 h). AKBA: Acetyl-11-keto-β-boswellic acid; PCNA: Proliferating cell nuclear antigen; GAPDH: Glyceraldehyde-phosphate dehydrogenase.

****


**Figure 3 Effects of acetyl-11-keto-β-boswellic acid on the expression of phosphatase and tensin homolog, cyclooxygenase-2, and p-Akt in gastric cancer cells.** A: Expression levels of phosphatase and tensin homolog (PTEN), cyclooxygenase (COX)-2, and p-Akt in gastric cancer cells measured *via* Western blot analysis; B: Histograms showing the relative expression levels of PTEN and COX-2 compared with GAPDH, and p-Akt compared with Akt in gastric cancer cells. Each data point represents the mean ± SD from three independent experiments. *aP* < 0.05, *bP* < 0.01 *vs* control (0 µM). AKBA: Acetyl-11-keto-β-boswellic acid; PTEN: Phosphatase and tensin homolog; COX-2: Cyclooxygenase-2; GAPDH: Glyceraldehyde-phosphate dehydrogenase.

****

**Figure 4 Effects of phosphatase and tensin homolog /Akt inhibitor on acetyl-11-keto-β-boswellic acid-induced down-regulation of cyclooxygenase-2 expression in gastric cancer cells.** Gastric cells were pre-treated with the phosphatase and tensin homolog (PTEN) inhibitor bpv (HOpic, 17.4 ng/mL, A and B) or Akt inhibitor MK2206 (38.4 ng/mL, C and D) for 30 min and then treated with acetyl-11-keto-β-boswellic acid (40 µM) for 48 h. A: Expression of PTEN, cyclooxygenase (COX)-2, and total and phosphorylated forms of Akt in gastric cancer cells detected by Western blot analysis. B: Histograms showing the relative expression of PTEN and COX-2 compared with GAPDH, and phospho-Akt (p-Akt) compared with total Akt, respectively. Each data point represents the mean ± SD from three independent experiments. *aP* < 0.05, *bP* < 0.01 *vs* Control; *cP* < 0.05, *dP* < 0.01 *vs* AKBA. AKBA: Acetyl-11-keto-β-boswellic acid; PTEN: Phosphatase and tensin homolog; COX-2: Cyclooxygenase-2; GAPDH: glyceraldehyde-phosphate dehydrogenase.

****

**Figure 5 Acetyl-11-keto-β-boswellic acid inhibits the monolayer wound healing of gastric cancer cells.** A and B: Phase micrographs of BGC823 and SGC7901 cells at various times after monolayer wounding (original magnification, × 100); C and D: Quantification of cell migration using monolayer wound-healing assay. The gastric cancer cells were treated without (control) or with 20 µM acetyl-11-keto-β-boswellic acid. Each data point represents the mean ± SD from three independent experiments. *aP* < 0.05, *bP* < 0.01 *vs* control (0 µM). AKBA: Acetyl-11-keto-β-boswellic acid.



**Figure 6 Acetyl-11-keto-β-boswellic acid inhibits gastric cancer tumor growth *in vivo*.** Twenty nude mice were subcutaneously injected with BGC823 and SGC7901 cells. When tumor size was approximately 0.1 cm3, the nude mice were randomly divided into different groups (*n* = 5) to receive different treatments. A: Acetyl-11-keto-β-boswellic acid (AKBA) inhibits gastric cancer xenograft tumor growth *in vivo*; B: Tumor volume was measured, and the tumor growth curves were plotted; C: Body weight change in the nude mice treated with saline or AKBA; D: Western blot analysis of cyclooxygenase (COX)-2 protein expression in gastric cancer tissues of control and AKBA treated nude mice (100 mg/kg/d); E: Histogram representing the relative expression of COX-2 compared with that of GAPDH. *aP* < 0.05, *bP* < 0.01 *vs* control (saline). AKBA: Acetyl-11-keto-β-boswellic acid.



**Figure 7 Hypothetical model of acetyl-11-keto-β-boswellic acid’s inhibition of proliferation of gastric cancer cells and induction of apoptosis.** AKBA: Acetyl-11-keto-β-boswellic acid; PTEN: Phosphatase and tensin homolog; COX-2: Cyclooxygenase-2; PCNA: Proliferating cell nuclear antigen.